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Abstract
Background Previously we described a system whereby human
peripheral blood T cells stimulated for 8 days in a cytokine
cocktail acquired effector function for contact-dependent
induction of proinflammatory cytokines from monocytes. We
termed these cells cytokine-activated (Tck) cells and found that
the signalling pathways elicited in the responding monocytes
were identical whether they were placed in contact with Tck
cells or with T cells isolated from rheumatoid arthritis (RA)
synovial tissue.
Methods Here, using magnetic beads and fluorescence-
activated cell sorting, we extensively phenotype the Tck effector
cells and conclude that effector function resides within the
CD4+CD45RO+, CCR7-, CD49dhigh population, and that these
cells are derived from the effector memory CD4+ T cells in
resting blood.
Results After stimulation in culture, these cells produce a wide
range of T-cell cytokines, undergo proliferation and differentiate
to acquire an extensively activated phenotype resembling RA
synovial T cells. Blocking antibodies against CD69, CD18, or
CD49d resulted in a reduction of tumour necrosis factor-α
production from monocytes stimulated with CD4+CD45RO+
Tck cells in the co-culture assay. Moreover, blockade of these
ligands also resulted in inhibition of spontaneous tumour
necrosis factor-α production in RA synovial mononuclear cell
cultures.
Conclusion Taken together, these data strengthen our
understanding of T-cell effector function, highlight the multiple
involvement of different cell surface ligands in cell-cell contact
and, provide novel insights into the pathogenesis of
inflammatory RA disease.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
brought about by the activities of cells and inflammatory
cytokines in the inflamed synovial membrane (for review [1]).
Cells found in diseased synovium are predominantly blood
derived, with large numbers of activated T cells and macro-
phages, fewer plasma cells and dendritic cells, together with
expanded numbers of resident fibroblasts and endothelial
cells [2]. Of the inflammatory cytokines, tumour necrosis factor
(TNF)-α [3] was demonstrated by us to be of pivotal impor-
tance in regulating the cytokine cascade in this tissue [2].
These and other studies led to the hypothesis that TNF-α was
a therapeutic candidate in RA [4], and the demonstration that
TNF-α blockade in murine arthritis ameliorated disease [5] led
to the testing of anti-TNF biologicals in humans [6-10]. Anti-
TNF biologicals are now licensed for use in RA and well over
CCR = CC chemokine receptor; CFSE = carboxyfluoroscein succinimidyl ester; CXCR = CXC chemokine receptor; ELISA = enzyme-linked immu-
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one million people worldwide have been treated with them.
Patients with other chronic inflammatory diseases have also
been treated with these drugs (for review [11]). Despite the
success of these anti-TNF biologicals, which protect joints
from destruction [12], they are not a cure, and blockade of
TNF-α has the potential to compromise the immune response
(for review [13]).
In contrast to the clearly defined role of macrophage-derived
cytokines in the pathogenesis of RA, the relevance and contri-
bution of the T cells is not clear and has been challenged [14].
In particular, the expectation that the increased T cells in the
synovium are a result of clonal expansion to a given antigen
has not been established. An human leucocyte antigen (HLA)-
restricted T-cell response to antigen is suggested, because
more than 80% of Caucasian RA sufferers have a shared
epitope conserved across the HLA-DR1 and HLA-DR4 haplo-
types (0101, 0401, 0404 and 1402) [15]. However, no overall
consensus has been reached on the potential autoantigens
involved. T-cell responses to collagen type II, heat shock pro-
teins and microbial antigens have been reported in a small pro-
portion of RA patients (for review [16]) and, more recently,
autoantibodies to deiminated citrullinated peptides have been
described, suggesting that they may be important autoanti-
gens in this disease. This aside, the concordance for disease
in identical twins is still less than 15%, suggesting that other
factors are of major importance.
More recently, we explored the mechanism(s) underlying
chronic production of TNF-α in RA synovium and found that
the spontaneous TNF-α production from macrophages is
dependent upon direct interaction with T cells found in this tis-
sue [17]. Several publications, principally from the Dayer
group, describe the ability of activated T cells to induce inflam-
matory mediator production from monocytes in a contact-
dependent manner [18-21]. T cells found in the synovial joint
tissue of RA patients are predominantly memory CD4+ cells
[22], with unusual characteristics in that they are small, non-
cycling and nonapoptosing, but have features of activation
[23]. We hypothesized that these T cells are stimulated in the
joint not as a consequence of antigen exposure but through
bystander cytokine-driven activation. To test our hypothesis,
we developed a surrogate model for RA T cells by stimulating
resting normal human peripheral blood lymphocytes with a
cocktail of cytokines (IL-2, IL-6 and TNF-α) for 8 days, as was
previously reported [24]. When fixed (to exclude mediators
released by the T cells) and placed in co-culture with mono-
cytes, proinflammatory cytokines and chemokines were pro-
duced in a cell contact-dependent manner [25,26].
Comparison of cytokine-activated T (Tck) cells with conven-
tional T-cell receptor stimulated T (Ttcr) cells activated by
immobilized anti-CD3 antibodies revealed the latter to be more
activated and stimulate monocytes to produce both IL-10 and
TNF-α [27]. In contrast, Tck cells induced only TNF-α and not
IL-10.
We postulated therefore that Tck cells are important in the
perpetuation of rheumatoid disease [25] because they induce
an unbalanced, proinflammatory cytokine response from
monocytes, and could thus form part of a vicious cycle. Fur-
thermore, we demonstrated that Tck cells mimicked RA T cells
in their effector function, because identical signalling path-
ways activated within the monocyte lead to TNF-α production
[17]. The monocyte phosphoinositide 3-kinase pathway and
the transcription factor NFκB were utilised in a similar manner
for induction of TNFα but was different from those induced by
the Ttcr cells [17]. More recently [26], we demonstrated that
contact-dependent induction of seven different chemokines in
monocytes was also identical between Tck and RA T cells in
the utilization of nuclear factor-κB in the monocyte signalling
pathway but different to that by co-culture with Ttcr cells.
In this paper we investigate the phenotype of the day 8 Tck
effector cells and, by using cell sorting methodologies, we
determine the phenotype of Tck cells and their precursors in
resting blood. Our results demonstrate that the most potent
Tck effectors are from a starting population of
CD4+CD45RO+ memory T cells. Furthermore, in culture these
cells divide, become activated and express increased levels of
activation, adhesion and integrin molecules. Comparison with
T cells extracted from the RA joint indicate that day 8 Tck cells
resemble RA T cells not only in their contact-dependent effec-
tor function but also in their active phenotype, with selective
upregulation of adhesion/integrin molecules (including very
late antigen [VLA]-4) that facilitate the extravasation of T cells
into inflamed tissues, including RA synovium.
Materials and methods
Reagents
IL-6 was kindly gifted by Novartis (Vienna, Austria), IL-2 from
the US National Institutes of Health, IL-10 from Schering
Plough (Kenilworth, NJ, USA), TNF-α from Boehringer Ingel-
heim (Biberach, Germany) and IFN-γ from Bender (Wien, Aus-
tria). Lipopolysaccharide (Salmonella typhimurium) was
purchased from Sigma (Gillingham, UK) and carboxyfluoros-
cein succinimidyl ester (CFSE) from Molecular Probes (Lei-
den, The Netherlands). Flow cytometry antibodies were
purchased from BD Pharmingen (Erembodegem, Belgium).
Blocking antibodies against CD18 (clone TS1/18) and
CD11a (clone HI111) were from BioLegend (Cambridge, UK),
anti-CD69 (clone TP1.55.3) was from Beckman Coulter (High
Wycombe, Buckinghamshire, UK) and anti-CD49d (clone TA-
2) was from Endogen (Rockford, Illinois, USA). Isotype control
antibody (mouse IgG1) was purchased from BD Pharmingen.
Cells cultured in RPMI/glutamine (PAA Laboratories,
Pasching, Germany) were supplemented with 10% normal AB
human serum (Sigma Aldrich, Dorset, UK) or 5% foetal calf
serum (Biowest, Nuaillé, France), as appropriate. All reagents
had under 0.1 units/ml of endotoxin, by LAL (limulus amebo-
cyte lysate) assay (BioWhittaker, Walkersville, MD, USA).Available online http://arthritis-research.com/content/10/2/R36
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Isolation of lymphocyte subpopulations by magnetic 
beads
Buffy coats were purchased from the North London Blood
Transfusion Service (Colindale, UK) and peripheral blood
mononuclear cells isolated by Lymphoprep™ (Cedarlane Lab-
oratories Ltd, Ontario, Canada) centrifugation followed by elu-
triation, as described previously [17]. Lymphocyte subsets
were isolated using CD4 or CD8 isolation kits (Dynal, Invitro-
gen, Paisley, UK), in accordance with the manufacturer's
instructions. CD45RO+ cells were isolated negatively using
memory CD4+ T-cell isolation kit from Miltenyi Biotec (Guild-
ford, Surrey, UK), in accordance with the manufacturer's
instructions.
Isolation of T cell sub-populations by cell sorting 
(fluorescence-activated cell sorting)
A cocktail of anti-CD4 with either anti-CD45RA or anti-
CD45RO antibodies was used to sort negatively for memory
or naïve populations, respectively. A cocktail of anti-CD4, anti-
CD45RA and anti-CCR7 (anti-CC chemokine receptor 7)
antibodies was used to sort the CD4+ central (CD45RA-
CCR7-) and effector memory (CD45RA-CCR7+) populations
on day 0. For the day 8 sort, CCR7 antibody was used to sort
positively the central and effector memory cells from the
CD4+CD45RO+ Tck population that was previously isolated
at day 0 using the memory CD4+ T-cell isolation kit from
Miltenyi Biotec, as described above. The resulting cell purity
was routinely assessed at more than 95%. Cells were sorted
on a FACSVantage SE (BD Biosciences, Cambridge, UK).
Tck generation and monocyte co-culture
Tck cells were generated from resting blood with IL-2, IL-6 and
TNF-α, as previously described [17]. Supernatants were har-
vested and T-cell-derived cytokine (IFN-γ, granulocyte macro-
phage colony-stimulating factor, lymphotoxin-α and IL-10)
levels were measured using sandwich ELISA (BD Pharmin-
gen). Tck cells were co-cultured with human peripheral blood
monocytes for 18 hours, as previously described [17], and
TNF-α levels in supernatants were assayed by sandwich
ELISA (Pharmingen, San Diego, CA).
Isolation of RA synovial membrane mononuclear cells 
and phenotypic analysis
Mononuclear cells were obtained from RA synovial tissue, as
previously described [17]. Tissues were from joint replace-
ment surgery specimens provided by the Orthopedic/Plastic
Surgery Department, Charing Cross Hospital, London, UK
(covered by ethics approval RREC 1752), after receiving
signed and informed patient consent and anonymization.
Peripheral blood lymphocytes or RA synovial mononuclear
cells were incubated with fluorochrome-labelled antibodies
and analyzed on a Becton-Dickinson LSR I flow cytometer (BD
Biosciences). A total of 5,000 synovial lymphocytes were col-
lected and results were analyzed using CellQuest Pro soft-
ware (BD Biosciences).
CFSE assay of cell proliferation
Lymphocytes were resuspended in phosphate-buffered saline
with 2.5 to 5 μmol/l CFSE at room temperature for 10 minutes
and washed extensively before culture. At day 8, cells were
counterstained with antibodies to cell surface markers. In all,
50,000 events were routinely collected by flow cytometry.
Blockade of CD18, CD69, CD49d and CD11a on Tck cells 
and RA synovial mononuclear cells
Day 8 Tck cells were fixed in 1% paraformaldehyde at 4°C
before incubation with 1.25 μg per million cells of blocking
antibody against CD18, CD69, CD49d, or CD11a. Isotype
control antibody was also included. After 30 minutes, Tck cells
were washed to remove excess antibodies and co-cultured
with fresh monocytes at a ratio of 8:1 in the presence of puri-
fied human IgG (5 μg/ml). Supernatants were collected after
18 hours and TNF-α was assayed by ELISA. RA synovial
mononuclear cells (MNCs) were incubated in triplicate for 24
hours at 0.5 × 106/ml in the presence or absence of 5 μg/ml
of blocking antibody against CD18, CD69, CD49d, or isotype
control. Supernatants were collected for TNF-α analysis by
ELISA.
Statistical analysis
Results were analysed using Prism 4 software (GraphPad
Software Inc., San Diego, CA, USA) and statistical differences
between groups were analyzed using Wilcoxon rank test, Stu-
dent's t-test, or one-way analysis of variance with Bonferroni
post hoc corrections as appropriate. Correlation association
between groups of data was analysed using nonparametric
(Spearman) correlation analysis.
Results
Phenotype of day eight Tck cells following cytokine 
stimulation
Figure 1a illustrates the CFSE dilution of Tck cells at day 8
counterstained for CD3 (Figure 1b), CD4 (Figure 1c), CD8
(Figure 1d) and CD56 (Figure 1e). At day 8 approximately
40% of cells were undivided (peak M1), whereas 60% of cells
(peaks M2 to M7) underwent up to six rounds of cell division
(Figure 1a). The CD3+CD4+  and CD3+CD8+  cells were
mostly found within the undivided population (M1; Figure
1b,c,d), whereas most CD56+ natural killer (NK) cells (Figure
1e) underwent several rounds of cell division. Pooling data
from seven different donors indicated that overall there was a
small increase in cell number from 1 million/ml at day 0 to 1.43
million/ml at day 8, accounted for predominantly by increases
in CD3-CD56+ NK cells from 0.07 to 0.25 million/ml (about
3.5-fold) and CD3+CD8+ T cells from 0.29 to 0.64 million/ml
(2-fold). CD3+CD4+ T cells numbers were increased less,
from 0.51 to 0.67 million/ml. CD19+ B cells did not survive the
8-day culture (data not shown).Arthritis Research & Therapy    Vol 10 No 2    Brennan et al.
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Tck effector function resides within the CD4+ T-cell 
subset
Figure 2a demonstrates that effector function (induction of
monocyte TNF-α in a dose-dependent manner from 500 to
800 pg/ml by day 8 Tcks) resided in cells derived at day 0 from
the CD4+ (P < 0.001) but not the CD4- population (which
included NK cells, CD8+ cells and NK T cells). Less TNF-α
(<100 pg/ml) was induced with day 8 Tck cells derived from
a starting population of CD4- cells (CD8+, NK T and NK cells).
To exclude the possibility that ligation of CD4 by the anti-CD4
magnetic beads affected the result, Figure 2b shows that the
CD8+ cells enriched at day 0 (which included CD8+ T cells
and NK T cells) did not induce an effector response at day 8
(<50 pg/ml). In contrast, the CD8- enriched cells (which were
predominantly CD4+ along with CD56+ NK cells) induced a
potent Tck effector response (P < 0.001) in a dose-dependent
manner at day 8 (75 to 875 pg/ml).
CD4+CD45RO+ (memory) Tck cells induce greater 
monocyte TNF-α
CD4+CD45RO+ (memory) T cells and CD4+CD45RA+ (naïve)
T cells [28], enriched at day 0 (Figure 3a), were sorted by flow
cytometry from the same donor based on CD45RA expression
and expanded for 8 days. Figure 3b demonstrates that the
memory T cells when cultured at a ratio of 1:1 with monocytes
induced significantly higher levels (P < 0.001) of TNF-α (6.7-
fold more) than did the naïve T cells at the comparable ratio.
This result was confirmed in five independent experiments.
The most potent inducers of monocyte TNF-α production
within the CD4+ memory population was found to reside within
the effector memory population (CD4+CD45RO+CCR7-), irre-
spective of whether the cells were sorted before ex vivo
cytokine expansion or afterward (Figure 3c). Sixfold more TNF-
α was produced by the effector memory cells (CCR7-) sepa-
rated at day 0 (P < 0.001) compared with central memory
cells (CCR7+) and about 13-fold more TNF-α produced by
effector memory cells separated at day 8 (P < 0.001) com-
pared with central memory cells. This result was confirmed in
three independent experiments.
Figure 1
Proliferation pattern of cytokine-stimulated lymphocytes Proliferation pattern of cytokine-stimulated lymphocytes. (a) Resting peripheral blood lymphocytes (PBLs) undergo cell divisions when they are stim-
ulated with cytokines over 8 days. Freshly elutriated lymphocytes were labeled with 5 μmol/l carboxyfluoroscein succinimidyl ester (CFSE) and stim-
ulated with IL-2, IL-6 and tumour necrosis factor-α for 8 days. The number of cell divisions was analysed on day 8 using CellQuest software. Markers 
(M1 to M7) indicate sequential cell divisions. (b-e) Proliferation of subpopulations of PBLs stimulated with cytokines. CFSE-labelled PBLs were 
counterstained with antibodies to CD3 (panel b), CD4 (panel c), CD8 (panel d) and CD56 (panel e). On day 8 the number of cell divisions for each 
subpopulation of PBLs was acquired and analyzed using CellQuest software. Results for all figures are shown from one donor representative of 
seven different experiments.Available online http://arthritis-research.com/content/10/2/R36
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Figure 2
The effector function of cytokine-stimulated lymphocytes resides within  the CD4+ population The effector function of cytokine-stimulated lymphocytes resides within 
the CD4+ population. (a) Effector function of the CD4+ cytokine-acti-
vated T (Tck) cell population compared with that of the CD4- Tck popu-
lation. Lymphocytes were positively separated using CD4+ magnetic 
beads (Dynal) before stimulation for 8 days with IL-2, IL-6 and tumour 
necrosis factor (TNF)-α. On day 8 lymphocytes were co-cultured with 
autologous monocytes (at the indicated ratios) for 18 hours before 
supernatants were removed and assayed for TNF-α by ELISA. Super-
natants from cultures of monocytes and T cells alone as negative con-
trols contained under 50 pg/ml. This experiment is representative of 
seven different donors. ***P < 0.001 comparing CD4+ versus CD4- at a 
ratio of 3:1, or comparing CD4+ versus CD4- at a ratio of 5:1 using one-
way analysis of variance (ANOVA) with Bonferroni's multiple compari-
son. Because of limited CD4- cell numbers, a comparison at a ratio of 
7:1 of could not be performed in this experiment. (b) Effector function 
of CD8+ Tck population compared with that of CD8- Tck population. 
Lymphocytes were positively separated using CD8+ magnetic beads 
(Dynal) before stimulation for 8 days with IL-2, IL-6 and TNF-α. On day 
8 lymphocytes were co-cultured with autologous monocytes (at the 
indicated ratios) for 18 hours before the supernatants were removed 
and assayed for TNF-α by ELISA. Supernatants from cultures of mono-
cytes and T cells alone as negative controls contained under 50 pg/ml. 
This experiment is representative of seven different donors. ***P < 
0.001 comparing CD8+ versus CD8- at a ratio of 5:1, or comparing 
CD8+ at versus CD8- at a ratio of 7:1 using one-way ANOVA with Bon-
ferroni's multiple comparison.
Figure 3
Memory T cells exhibit greater effector function than naïve T cells Memory T cells exhibit greater effector function than naïve T cells. (a) 
Fluorescence-activated cell sorting analysis of CD4+ subpopulations. 
Resting CD4+ lymphocytes in normal peripheral blood contains 
CD45RA+CCR7+ (naïve) lymphocytes (left panel) together with 
CD45RO+CCR7+ central memory (TCM; right panel) and 
CD45RO+CCR7- effector memory populations (TEM; right panel). (b) 
Effector function resides mainly within the CD4+CD45RO+ population. 
Lymphocytes were sorted into naïve (CD4+CD45RA+) and memory 
(CD4+CD45RO+) populations at time zero, before stimulation for 8 
days with IL-2, IL-6 and tumour necrosis factor (TNF)-α. Lymphocytes 
were then co-cultured with monocytes at a ratio of 0.5:1 and 1:1 for 18 
hours and the supernatants assayed in triplicate for TNF-α production 
by ELISA. ***P < 0.001 comparing CD4+CD45RA+ versus 
CD4+CD45RO+ populations using one-way analysis of variance 
(ANOVA) with Bonferroni's multiple comparison. (c) Effector function 
resides predominates within CD4+ effector memory population. 
CD45RO+ cells were further sorted by flow cytometry into CCR7+ and 
CCR7- populations at day 0 (and stimulated for 8 days with cytokines) 
or at day 8 (after cytokine expansion) and then co-cultured with mono-
cytes at a ratio of 1:1 for 18 hours, and the supernatants assayed in 
triplicate for TNF-α production by ELISA. ***P < 0.001 comparing 
CD4+CD45RO+CCR7- versus CD4+CD45RO+CCR7+ after sorting at 
day 0 sort or at day 8 using one-way ANOVA with Bonferroni's multiple 
comparison. In panels b and c monocytes and T cells cultured alone as 
negative controls produced under 20 pg/ml TNF-α. Results are shown 
from one donor representative of five different experiments (panel b) 
and three different experiments (panel c). CCR, CC chemokine 
receptor.Arthritis Research & Therapy    Vol 10 No 2    Brennan et al.
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Phenotype of day eight CD4+CD45RO+ Tck cells after 
cytokine stimulation
Table 1 summarizes the pooled median mean fluorescence
intensity (MFI) values and percentage of cells positive for cell
surface molecules at days 0 and 8 on the CD4+CD45RO+
cells from independent experiments. T-cell activation markers
(CD25, CD69 and HLA-DR) were significantly increased at
day 8, with median MFI increases of greater than sevenfold for
CD25 (P < 0.0001), eightfold for CD69 (P < 0.0001) and
threefold for HLA-DR (P = 0.0052), respectively. CD25+ cells
increased from 9% at day 0 to 18% at day 8, indicating expan-
sion of some cells in culture. Day 8 Tck cells also exhibited a
significant increase in CD69 expression (Table 1), with 27%
of the cells positive for CD69 at day 8. HLA-DR was also
increased but to a lesser extent, from 9% at day 0 to 15% at
day 8.
Table 1
Expression of activation markers, adhesion molecules and chemokine receptors in CD4+CD45RO+ Tck cells
Cell phenotype Median MFI (range)/percentage positive (%) index Changea Pn
Day 0 Day 8
CD25 8.0 (2–49)/9% 61 (6–884)/18% 7.5 <0.0001 40
CD69 5.0 (2–43)/1.1% 41 (5–552)/26.7% 8 <0.0001 41
HLA-DR 19 (4–130)/9% 60 (11–238)/15% 3 0.0052 15
CD62L 22 (8–255)/17% 339 (7–1,040)/58% 15 <0.0001 31
CD18 107 (9–1,026)/97.5% 319 (53–2,040)/98.5% 3 0.0085 21
CD29 85 (6–668)/81% 152 (14–582)/97% 2 0.0132 35
CD49d 180 (5–634)/73.3% 465 (13–1,461)/82.3% 2.6 <0.0001 42
CCR7 12 (4–57)/7.4% 13 (3–138)/8.6% 1 NS 42
CXCR4 52 (18–494)/29% 270 (124–896)/86.4% 5 <0.0001 21
CXCR3 32.3 (9–309)/34.3% 40.4 (17–129)/34.0% 1 NS 21
CCR5 8.3 (4–28)/2% 10.7 (4–262)/6% 1 NS 21
Statistically significant differences in mean fluorescence intensity (MFI) between day 0 and day 8 values from different experiments were 
calculated using Wilcoxon rank test. aChange index is calculated with reference to Day 0. CCR, CC chemokine receptor; CXCR, CXC chemokine 
receptor; HLA, human leucocyte antigen; NS, not significant; Tck, cytokine-activated T.
Table 2
Relationship between day 8 Tck phenotype (MFI) and effector function (TNF-α production from co-cultured monocytes)
Cell phenotype nr   (correlation) P
CD25 40 -0.2558 NS
CD69 41 0.00053 NS
HLA-DR 15 0.4094 NS
CD62L 31 -0.4652 0.00084
CD18 21 0.1442 NS
CD29 35 0.2167 NS
CD49d 42 0.3314 0.032
CCR7 42 -0.1711 NS
CXCR4 21 -0.13 NS
CXCR3 21 0.02341 NS
CCR5 21 -0.3948 NS
Day 8 expression of cell surface markers (mean fluorescence intensity [MFI]) was correlated with effector function (tumour necrosis factor [TNF]-
α production from monocytes in cytokine-activated T [Tck] cell:monocyte co-culture) using nonparametric (Spearman) correlation analysis. 
Results are expressed as correlation values (r) and level of significance.Available online http://arthritis-research.com/content/10/2/R36
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Adhesion marker expression was more variable. Firstly, L-
selectin (CD62L), a potential marker of central memory cells
was upregulated (15-fold) in the day 8 Tck cells (P < 0.0001).
An expansion in the central memory population is not likely
because CCR7+ expression (a more robust marker of central
memory cells) remained low in the day 8 CD4+CD45RO+ Tck
cells (Table 1). Interestingly, CD62L expression peaked at day
6, followed by a significant decrease in expression at day 8
(data not shown). This coincided with detection of soluble
CD62L in the culture supernatants (>150 ng/ml by day 6),
indicating shedding of CD62L (data not shown). Using non-
parametric (Spearman) correlation analysis (Table 2), it was
observed that CD62L expression at day 8 negatively corre-
lated (r = -0.4652; P = 0.00084) with TNF-α production in the
co-culture system (n = 31).
The proportions of cells positive for the adhesion markers
CD18, CD29 and CD49d did not increase substantially in cul-
ture, because more than 70% of the resting cells were already
positive for these markers at day 0. However, the median MFI
expression did increase for each molecule, with threefold
(CD18; P < 0.0085), twofold (CD29; P = 0.0132) and three-
fold (CD49d; P < 0.0001) increases at day 8. Interestingly,
using nonparametric (Spearman) correlation analysis (Table
2), it was observed that VLA-4 (CD49d) expression at day 8
positively correlated (r = 0.3314; P < 0.032) with TNF-α pro-
duction in the co-culture system (n = 42). It is unlikely that this
ligand is binding vascular cell adhesion molecule (VCAM)-1
(its counter ligand) on monocytes because this molecule is not
found on peripheral blood monocytes. However, this may indi-
cate that the most activated cells have the potent effector
function in the co-culture assay and that CD49d is a surrogate
marker for this activity.
Chemokine receptor expression was variable and lower than
that of the adhesion molecules. Only CXC chemokine recep-
tor (CXCR)4 increased significantly (fivefold; P  < 0.0001)
over the 8-day culture period, with 86% cells positive at day 8
compared with 29% at day 0. Increases in CXCR3 and CCR5
expression were also observed but did not reach statistical
significance. Levels of CCR7 marker for naïve (CD45RA+) and
central memory (CD45RO+) cells were low (3%) and
remained unchanged over the 8-day period.
Phenotype of proliferated CD4+CD45RO+ Tck cells 
following cytokine stimulation
Figure 4a illustrates the CFSE dilution of CD4+CD45RO+ Tck
cells at day 8 (representative of four different donors) counter-
stained for CD25 (Figure 4b), CD69 (Figure 4c), CD18 (Fig-
ure 4d) and CD49d (Figure 4e). Over four independent
donors, an average of 55% of cells were undivided (M1)
whereas 45% of cells (peaks M2 to M7) underwent up to six
rounds of cell divisions. The MFI of both activation markers and
adhesion molecules were found to be higher in the divided
population. The MFI of CD25 (Figure 4b) was 3,219 in the
divided as compared with 2,126 in undivided cells; the MFI of
CD69 (Figure 4c) was 1,881 compared with 788; the MFI of
CD18 (Figure 4d) was 7,312 compared with 2,693; and
CD49d expression (Figure 4e) was 10,121 compared with
5,102.
Day 8 CD4+CD45RO+ Tck cells phenotypically resemble 
RA synovial T cells
Figure 5 illustrates the phenotype from a representative exper-
iment using peripheral blood CD4+CD45RO+ lymphocytes at
day 0 (left) and after 8 days of culture with cytokines (middle)
compared with CD4+ T cells within RA synovial membrane tis-
sue (right). CD25 expression was present in a small proportion
(9%) of resting lymphocytes, which was increased (18%) on
Figure 4
Proliferation pattern and phenotype of day 8 CD4+CD45RO+ Tck cells  after cytokine stimulation Proliferation pattern and phenotype of day 8 CD4+CD45RO+ Tck cells 
after cytokine stimulation. Freshly isolated CD4+CD45RO+ cells were 
labeled with 2.5 μmol/l carboxyfluoroscein succinimidyl ester and stim-
ulated with IL-2, IL-6 and tumour necrosis factor (TNF)-α for 8 days. (a) 
The number of cell divisions was analyzed on day 8 using FlowJo 7.2.2 
software (Tree Star, Inc., Oregon, USA). Cells were counterstained 
with antibodies against (b) CD25, (c) CD69, (d) CD18 and (e) 
CD49d, with mean fluorescent intensity (MFI) of these markers 
assessed in the undivided (M1) peak versus the divided (M2 to M7) 
fractions. Results are shown in the gates. Figure representative of four 
independent experiments. Tck cell, cytokine-activated T cell.Arthritis Research & Therapy    Vol 10 No 2    Brennan et al.
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day 8 Tck cells. A small proportion of RA synovial T cells in this
sample were also CD25+ but not to the same extent as day 8
Tck cells. The activation markers CD69 and HLA-DR were
clearly elevated on day 8 Tck cells and were similarly elevated
on RA synovial T cells. CD62L was absent from resting T cells
but increased on the day 8 Tck cells. However, RA synovial T
cells were negative for this selectin. Adhesion molecules
CD18, CD29 and CD49d were present on resting T cells but
further upregulated in day 8 Tck cells, with similar expression
to that seen on RA synovial T cells. The chemokine receptor
CCR7, a 'marker' of naïve and central memory T cells, was
expressed on the day 0 resting T cells. Its expression was
absent on the RA synovial T cells and day 8 Tck cells. The
chemokine receptors CXCR4, CXCR3 and CCR5 were all
increased on day 8 Tck cells to varying extents, but in the RA
synovial tissue examined here only CXCR3 was found to be
upregulated on the RA synovial T cells. However, on the other
RA synovial specimens examined (data not shown) both
CXCR4 and CCR5 expression was abundant, which is con-
sistent with numerous published reports (for review [29]).
Day 8 CD4+CD45RO+ Tck effector function is blocked 
with neutralizing antibodies to CD69, CD18 and CD49d
Having demonstrated that day 8 CD4+CD45RO+ Tck cells
exhibit a differentiated phenotype, we next determined
whether blocking these surface molecules with neutralizing
antibodies would result in inhibition of the effector response.
Thus, in a series of experiments CD4+CD45RO+ Tck cells
were pre-incubated with neutralizing antibodies to CD69,
CD18, CD49d, CD11a, or isotype control antibodies (as
described in Materials and methods, above), and TNF-α
production from monocytes was assessed in the co-culture
assay. In three independent experiments (Figure 6a), blockade
of CD69 resulted in an overall inhibition of 37% (P < 0.05),
with TNF-α levels reduced from 479.6 ± 310.3 pg/ml to 227.7
± 79.6 pg/ml. Blockade of CD18 resulted in an overall inhibi-
tion of 50% (P < 0.01) with TNF-α levels reduced from 479.6
± 310.3 pg/ml to 183.8 ± 48.5 pg/ml. Blockade of CD49d
resulted in 70% inhibition of TNF-α production from 69 ± 24
pg/ml to 10 ± 5 pg/ml (P = 0.04) in one experiment, although
in a further three experiments no inhibition was observed (data
not shown). Blockade of CD11a had no effect (data not
shown).
Spontaneous production of TNF-α and IL-6 is blocked in 
RA synovial MNC cultures with neutralizing antibodies 
to CD69, CD18, or CD49d
Having demonstrated that day 8 CD4+CD45RO+ Tck cells
phenotypically resemble RA synovial T cells, we next explored
whether ligation events involving CD69, CD18, or VLA-4
(CD49d) were instrumental in inducing/maintaining
proinflammatory cytokine production in RA synovial MNC ex
vivo cultures. Thus, in a series of experiments on different RA
donors, synovial MNC cells were incubated in triplicate in the
presence or absence of neutralizing antibodies to CD69,
CD18, CD49d, or an isotype control. Table 3 illustrates the
percentage inhibition of spontaneous TNF-α production from
Figure 5
Day 8 CD4+CD45RO+ Tck cells phenotypically resemble rheumatoid  synovial T cells Day 8 CD4+CD45RO+ Tck cells phenotypically resemble rheumatoid 
synovial T cells. Freshly elutriated peripheral blood lymphocytes (PBLs) 
from healthy donors were stained with antibodies against CD4 and 
CD45RO in combination with antibodies against CD25, CD69, HLA-
DR, CD62L, CD18, CD29, CD49d, CCR7, CXCR4, CXCR3, or 
CCR5 at time 0 (left panels) and day 8 (middle panels) after culture 
with IL-2, IL-6 and tumour necrosis factor (TNF)-α (as detailed in Mate-
rials and methods). Rheumatoid synovial cells were also stained with 
the same panel of antibodies as PBLs. In all, 1 × 104 PBLs and 5 × 103 
synovial T cells were collected and the expression of different cell mark-
ers on the CD4+ gated lymphocyte population versus CD45RO+ 
expression was analyzed on the CellQuest Pro software. CCR, CC 
chemokine receptor; CXCR, CXC chemokine receptor; HLA, human 
leucocyte antigen.Available online http://arthritis-research.com/content/10/2/R36
Page 9 of 13
(page number not for citation purposes)
four different RA synovial MNC cultures compared with cells
only control (similar levels were obtained with isotype antibody
control). Blockade of CD69 had a modest (approximately
21%) inhibitory effect upon TNF-α production in all RA syno-
vial cultures, although in one of these donors this change was
not significant (Table 3). Blockade of CD18 resulted in TNF-α
inhibition in three out of the four donor RA cultures, with as
much as 50% inhibition observed in donor 4. Blockade of
CD49d resulted in inhibition of TNF-α in only two out of the
four RA donor cultures. In RA donor two (Figure 6b), blockade
of CD69, CD18, or CD49d all resulted in significant inhibition
TNF-α production (data illustrated as mean TNF-α production
[pg/ml] from triplicate cultures).
Cytokine production by CD4+CD45RO+ Tck cells in 
culture
Supernatants from the day 8 culture CD4+CD45RO+ Tck cells
were screened for T-cell cytokines and significant amounts of
lymphotoxin-α (median 358 pg/ml), IFN-γ (median 534 pg/ml)
and GM-CSF (median 2,095 pg/ml) were found, with lesser
amounts of IL-10 (median 30 pg/ml; Table 4). IL-17 was not
detected in the Tck culture supernatants at day 8 but was
induced if at day 5 the Tck cell cultures were treated with 2 ng/
ml recombinant IL-23 (data not shown).
Discussion
Although TNF-α is now acknowledged to be important in the
pathology of RA [11], the mechanisms that lead to its dysreg-
ulated production remain unknown but are of importance to
the development of improved therapies. Several pieces of evi-
dence from our group and others have emerged to indicate
that macrophage-derived TNF-α in inflamed synovial tissue is
T cell and contact dependent [17,21,30-32]. In order to study
this mechanism in more detail, we developed a human surro-
gate model system based on cytokine activation of peripheral
blood lymphocytes, and found that after 8 days these cytokine-
activated T cells (but not those activated by crosslinked anti-
CD3) mimicked the effector function of rheumatoid T cells
[17,25]. Importantly, the differences between Tck cells and
those derived from antigen activation provided an opportunity
for selective inhibition of pathogenic T cells. In this report we
characterize the generation of day 8 Tck cells in terms of the
induced lymphocyte proliferation, cell surface phenotype and
cytokine production. Furthermore, by a series of cell sorting
experiments, we not only identify the phenotype of the most
potent effector cell at day 8 but also, based upon this knowl-
edge, uncover the precursor phenotype of Tck cells within nor-
mal resting peripheral blood lymphocyte population. This may
have implications for our understanding of the generation of
pathogenic T cells in the highly proinflammatory environment
of the rheumatoid synovium.
Analysis of the lymphocytes expanded from human peripheral
blood with the cytokine cocktail in our day 8 Tck cultures
revealed a significant expansion in CD3-CD56+ cells (NK
population), with a lower overall change in the number of
CD3+CD56- T cells over the 8 days, despite cell division within
the CD8+ population. The lack of change in total cell number
at day 8 is apparently due to apoptosis in approximately 30%
of the CD3+ cells (data not shown), most likely because of
Figure 6
CD69, CD18 and CD49d blockade resulted in reduced TNF-α in Tck  co-cultures and rheumatoid synovium culture CD69, CD18 and CD49d blockade resulted in reduced TNF-α in Tck 
co-cultures and rheumatoid synovium culture. (a) CD4+CD45RO+ cells 
were fixed after 8 days of cytokine stimulation with 1% paraformalde-
hyde and then co-incubated with blocking antibodies against CD18 
and CD69, as described in Materials and methods. Cytokine-activated 
T (Tck) cells were co-cultured with fresh monocytes at a ratio of 8:1. 
Supernatants were harvested after 18 hours and TNF-a production 
measured by ELISA. This figure represents three experiments con-
ducted in different donors. (b) Rheumatoid arthritis (RA) synovial cell 
mononuclear cells from RA donor 2 (see Table 3) were cultured in trip-
licate in the presence of antibodies against CD69, CD18, or CD49d 
for 24 hours, as described in Materials and methods. Supernatants 
were harvested and spontaneous TNF-α production was measured 
using ELISA. **P < 0.01 and *P < 0.05, as assessed by one-way analy-
sis of variance with post hoc Bonferroni correction.Arthritis Research & Therapy    Vol 10 No 2    Brennan et al.
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depletion of growth factors in these cultures, particularly when
expanded together with the rapidly proliferating NK cells.
Indeed, if the human peripheral blood lymphocytes were
expanded with IL-15 alone (previously to generate effective
Tcks cells [25]), the expansion of NK cells at day 8 was even
more marked. Furthermore, if the NK cells were separated at
day 8 from the CD3+ T cells, they also exhibited contact
effector function on monocytes but in a phosphoinositide 3-
kinase dependent manner (unpublished data), similar to that
induced by anti-CD3 antibody stimulated peripheral blood
lymphocytes [17,26,33]. Only the CD3+ cells within the day 8
Tck cells (and not the CD3-CD56+) exhibited effector function
identical to that of RA synovial T cells, and thus we focused
our attention on these cells.
Closer analysis and enrichment of the CD3+ subset phenotype
(at either day 0 or day 8) revealed that the most efficient
effector cell resided within the CD3+CD4+CD45RO+ memory
subset, and more specifically within the effector memory pop-
ulation (CCR7-). The day 8 Tck cells resembled RA synovial T
cells, particularly in terms of the increased expression of sev-
eral adhesion molecules including VLA-4. The latter is of par-
ticular interest because, based on its overall expression at day
8, it was the only ligand to correlate positively with the ability
to induce monocyte production of TNF-α (Table 2). Synovial T
cells express high levels of both the alpha (CD49d) and beta
(CD29) chains of VLA-4 and exhibit ex vivo an enhanced abil-
ity to bind to fibronectin fragments (a VLA-4 ligand) [34]. Fur-
thermore, an alternate VLA-4 ligand, namely VCAM-1, is
expressed selectively on RA endothelium and macrophages in
the lining layer of the synovium, and is inhibited following anti-
TNF-α therapy in the clinic [35]. It has been hypothesized that
VLA-4 facilitates extravasation of lymphocytes across
endothelium (via VCAM-1) and their retention in the joint tissue
(via fibronectin binding and/or VCAM-1). To investigate this
further, we intend to explore the ability of VLA-4high Tck cells to
extravasate endothelium in ex vivo cultures. Furthermore (and
potentially of greater interest), we will determine the ability of
CD4+CD45RO+VLA-4high Tck cells to traffic to synovial grafts
in the RA/severe combined immunodeficient mouse model,
together with their potential to upregulate cytokines locally in
this tissue.
The fact that the resting CD4+CD45RO+ T cells from normal
blood are unable to induce TNF-α from monocytes indicates
that this effector function is acquired either due to de novo
gene transcription and/or conformational change of a surface
molecule during the differentiation process. Several cell sur-
face molecules, including integrins and adhesion molecules,
have previously been shown to be of importance in contact-
dependent effector function, including CD69 [19], lymphocyte
function-associated antigen-1 (CD11a and CD18) and others
[18,36]. We confirmed that blockade of CD18 and CD69 on
Tck cells reduced monocyte TNF-α production in the co-cul-
Table 3
Modulatory effect on spontaneous TNF-α production following blockade of cell surface ligands in RA MNC cultures
RA donor Anti-CD69 Anti-CD18 Anti-CD49d
Inhibition (%) P Inhibition (%) P Inhibition (%) P
11 7 < 0 . 0 1 0N S 0N S
2 23 <0.05 22 <0.01 36 <0.01
3 2 2 N S2 6 N S2 3 N S
4N D N S 5 1 < 0 . 0 1 0N S
Rheumatoid arthritis (RA) synovial mononuclear cell (MNC) cells were cultured in triplicate with anti-CD69, anti-CD18, or anti-CD49d antibodies 
at a final concentration of 5 μg/ml for 24 hours at 37°C, as described in Materials and methods. Spontaneous tumour necrosis factor (TNF)-α 
production was measured in the supernatants by ELISA and results expressed as percentage inhibition relative to the control wells (cells only). 
Significance (P value) was calculated using one-way analysis of variance with post hoc Bonferroni correction.
Table 4
Cytokine levels found in day 8 CD4+CD45RO+ Tck cell culture supernatants
Cytokine n Median levels (pg/ml) Range (pg/ml)
Lymphotoxin-α 25 358 (38–7,306)
IFN-γ 32 534 (8–21,280)
GM-CSF 21 2,095 (603–8,043)
IL-10 36 30 (0–310)
Supernatants from day 8 cytokine-activated T (Tck) cell cultures were harvested and cytokines detected by ELISA, as described in Materials and 
methods. GM-CSF, granulocyte monocyte colony-stimulating factor.Available online http://arthritis-research.com/content/10/2/R36
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ture system, which is in agreement with previous studies
[19,21,36]; also, in one single experiment blockade of CD49d
(VLA-4) also reduced monocyte TNF-α production. More
importantly, the role of these cell surface ligands was verified
in the present study using the ex vivo RA synovial MNC culture
system, reinforcing the relevance of Tck cells as surrogates for
RA synovial T cells, and highlighting the potential role of these
ligands in contributing to chronicity in RA. However, it is note-
worthy that none of these ligation events were dominant in
either system, and several different ligation events are poten-
tially 'involved' in these contact-mediated events in inflamma-
tory tissue, as was previously described [19].
VLA-4 also probably plays a role in trafficking of T cells to the
synovial microenvironment (as discussed above). Interestingly,
the chemokine receptor CXCR4 previously identified on RA
synovial T cells [37] was also increased on day 8 Tck cells.
CXCR4 plays a key role in trafficking T cells to inflamed syn-
ovium in response to ligands including stromal cell-derived
factor-1 [37,38]. Therefore, antigen-independent activation by
proinflammatory cytokines could not only induce cells capable
of perpetuating disease by cellular contact with monocytes
but also facilitate the accumulation of these pathogenic cells
at the site of disease. We are currently exploring the role of
VLA-4 (as discussed above), together with CXCR4 and stro-
mal cell-derived factor-1, in migration of these Tck cells in vivo
in the RA/SCID mouse model.
Although the series of cell sorting experiments indicated that
enriching for CD4+CD45RO+ T cells increased the Tck effec-
tor potency, variation between different experiments with dif-
ferent donors was very evident. One possible explanation is
that regulatory T cells (or factors) are present in the cultures
and suppress Tck effector function, either by modulating the
generation of effector Tck cells and/or by modulating the abil-
ity of the monocytes to produce TNF-α after contact activation
[39]. Consistent with this hypothesis was our observation that
the proportion of CD4+CD25+ cells increased in the Tck cul-
tures (Table 1) and were found within the dividing population
of CD4+CD45RO+ cells (Figure 4a). We have preliminary data
showing that CD25+Foxp3+CD127- regulatory T cells are
present in these Tck cultures and that they expand over the 8-
day culture period at a faster rate than the Tck effector cells.
Therefore, although the phenotype of the divided
CD4+CD45RO+ cells (Figure 4a) expressed more surface
activation and adhesion molecules, including CD49d (Figure
4e), they may not necessarily be more potent effectors than
the nondivided CD4+CD45RO+  cells because
CD25+Foxp3+CD127-  regulatory T cells are also present
within these populations. We are currently determining in a
separate and extensive study the modulatory effect of these
CD25+Foxp3+CD127- regulatory T cells upon the expansion
of Tck cells, the acquisition of effector function and the direct
effect on the monocytes in the co-culture model. In the RA syn-
ovial tissue we examined in this report (Figure 5), the propor-
tion of CD4+CD25+ cells was relatively low compared with
that in other published reports. However, there is inconsist-
ency in the published reports, with several describing an
increase in the proportion of CD25+Foxp3+CD127- regulatory
T cells in the synovial fluid [40,41] and others describing a
reduction in synovium compared with synovial fluid [42].
Conclusion
The present study extends our previous observations on
cytokine-activated T cells (Tck cells) and their potential in
contributing to chronicity in inflammation. We found that
CD4+CD45RO+CCR7- effector memory T cells differentiate
to an effector population upon cytokine stimulation in vitro,
which mimics RA synovial T cells both in effector function and
cell surface phenotype. By defining the phenotype of effector
Tck cells, we have focused studies to gain further insight into
the exact nature of contact-dependent activation of macro-
phages in RA. The cell surface molecules CD69, CD18 and
CD49d were shown to plays roles in these contact-mediated
events. The pathogenic potential of Tck cells is currently being
explored further in the RA/severe combined immunodeficient
model, which will also allow us to explore the modulatory
effects of blocking candidate cell surface proteins on migra-
tory cells and determine their effect on the pathogenesis of
disease.
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